Table 1.
Baseline demographic and clinical characteristics of chronic hepatitis C patients.
| Characteristics | n = 88 |
|---|---|
| Age in years, mean ± SD (min–max) | 59.4 ± 8.95 (23.0–73.0) |
| Gender, n (%) | |
| Female/male | 61 (69.32)/27 (30.68) |
| HCV genotype, n (%) | |
| 1 | 71 (80.68) |
| 3 | 16 (18.18) |
| 4 | 1 (1.14) |
| HCV viral load (IU/mL), mean (±SD) | 17.7 × 105 (±34.7 × 105) |
| Liver disease status, n (%) | |
| F0–F3 | 17.0 (19.32) |
| F4 | |
| Child A | 58.0 (65.91) |
| Child B or C | 13.0 (14.77) |
| ALT (U/L), median (IQR) | 99.0 (64.5–134.8) |
| AST (U/L), median (IQR) | 73.5 (46.2–117.0) |
| Albumin (g/dL), median (IQR) | 3.45 (3.1–3.8) |
| PT (seconds), median (IQR) | 13.0 (12.2–14.3) |
| INR, median (IQR) | 1.18 (1.11–1.3) |
| Previous therapy, n (%) | 50.0 (56.82) |
| Current therapy, n (%) | |
| SOF + DCV | 12.0 (13.64) |
| SOF + DCV + RBV | 55.0 (62.50) |
| SOF + SMV | 8.0 (9.09) |
| SOF + SMV + RBV | 13.0 (14.77) |
| Therapy duration, n (%) | |
| 12 weeks | 75.0 (85.23) |
| 24 weeks | 13.0 (14.77) |
| Therapy outcome, n (%) | |
| SVR | 87.0 (98.86) |
| Relapse | 1.0 (1.14) |
Data are expressed as mean (±SD) or n (%). ALT: alanine aminotransferase; AST: aspartate aminotransferase; DCV: daclatasvir; GGT: gamma-glutamyl transferase; HCV: hepatitis C virus; IQR: interquartile range; RBV: ribavirin; SD: standard deviation; SOF: sofosbuvir; SMV: simeprevir.